212 related articles for article (PubMed ID: 27899115)
1. Characterizing the impact of sustained sulfadoxine/pyrimethamine use upon the Plasmodium falciparum population in Malawi.
Ravenhall M; Benavente ED; Mipando M; Jensen AT; Sutherland CJ; Roper C; Sepúlveda N; Kwiatkowski DP; Montgomery J; Phiri KS; Terlouw A; Craig A; Campino S; Ocholla H; Clark TG
Malar J; 2016 Nov; 15(1):575. PubMed ID: 27899115
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
Bwijo B; Kaneko A; Takechi M; Zungu IL; Moriyama Y; Lum JK; Tsukahara T; Mita T; Takahashi N; Bergqvist Y; Björkman A; Kobayakawa T
Acta Trop; 2003 Mar; 85(3):363-73. PubMed ID: 12659974
[TBL] [Abstract][Full Text] [Related]
3. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
Kateera F; Nsobya SL; Tukwasibwe S; Hakizimana E; Mutesa L; Mens PF; Grobusch MP; van Vugt M; Kumar N
Acta Trop; 2016 Dec; 164():329-336. PubMed ID: 27647575
[TBL] [Abstract][Full Text] [Related]
4. Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi.
Artimovich E; Schneider K; Taylor TE; Kublin JG; Dzinjalamala FK; Escalante AA; Plowe CV; Laufer MK; Takala-Harrison S
J Infect Dis; 2015 Sep; 212(5):694-701. PubMed ID: 25672905
[TBL] [Abstract][Full Text] [Related]
5. The evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: comparing selection under SP alone vs SP+artesunate combination.
Malisa AL; Pearce RJ; Mutayoba BM; Abdullah S; Mshinda H; Kachur PS; Bloland P; Roper C
Malar J; 2011 Oct; 10():317. PubMed ID: 22029848
[TBL] [Abstract][Full Text] [Related]
6. Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study.
Chaponda EB; Mharakurwa S; Michelo C; Bruce J; Chandramoha D; Matthew Chico R
Malar J; 2021 Jan; 20(1):61. PubMed ID: 33482823
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
Happi CT; Gbotosho GO; Folarin OA; Akinboye DO; Yusuf BO; Ebong OO; Sowunmi A; Kyle DE; Milhous W; Wirth DF; Oduola AM
Acta Trop; 2005 Sep; 95(3):183-93. PubMed ID: 16023986
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of the 437G mutation associated with sulfadoxine resistance among Plasmodium falciparum clinical isolates from Iran, three years after the introduction of sulfadoxine-pyrimethamine.
Zakeri S; Farahani MS; Afsharpad M; Salehi M; Raeisi A; Djadid ND
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e123-8. PubMed ID: 20399698
[TBL] [Abstract][Full Text] [Related]
9. Frequencies distribution of dihydrofolate reductase and dihydropteroate synthetase mutant alleles associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum population from Hadhramout Governorate, Yemen.
Bamaga OA; Mahdy MA; Lim YA
Malar J; 2015 Dec; 14():516. PubMed ID: 26693691
[TBL] [Abstract][Full Text] [Related]
10. Molecular monitoring of resistant dhfr and dhps allelic haplotypes in Morogoro and Mvomero districts in south eastern Tanzania.
Malisa A; Pearce R; Abdullah S; Mutayoba B; Mshinda H; Kachur P; Bloland P; Roper C
Afr Health Sci; 2011 Jun; 11(2):142-50. PubMed ID: 21857842
[TBL] [Abstract][Full Text] [Related]
11. Prevailing Plasmodium falciparum dihydrofolate reductase 108-asparagine in Hodeidah, Yemen: a questionable sulfadoxine-pyrimethamine partner within the artemisinin-based combination therapy.
Abdul-Ghani R; Farag HF; Allam AF; Shawky SM
Acta Trop; 2014 Apr; 132():39-44. PubMed ID: 24406851
[TBL] [Abstract][Full Text] [Related]
12. Molecular evidence of increased resistance to anti-folate drugs in Plasmodium falciparum in North-East India: a signal for potential failure of artemisinin plus sulphadoxine-pyrimethamine combination therapy.
Mohapatra PK; Sarma DK; Prakash A; Bora K; Ahmed MA; Sarma B; Goswami BK; Bhattacharyya DR; Mahanta J
PLoS One; 2014; 9(9):e105562. PubMed ID: 25184337
[TBL] [Abstract][Full Text] [Related]
13. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment.
Eriksen J; Mwankusye S; Mduma S; Kitua A; Swedberg G; Tomson G; Gustafsson LL; Warsame M
Trans R Soc Trop Med Hyg; 2004 Jun; 98(6):347-53. PubMed ID: 15099990
[TBL] [Abstract][Full Text] [Related]
14. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance.
Griffin JT; Cairns M; Ghani AC; Roper C; Schellenberg D; Carneiro I; Newman RD; Grobusch MP; Greenwood B; Chandramohan D; Gosling RD
PLoS One; 2010 Sep; 5(9):e12618. PubMed ID: 20838642
[TBL] [Abstract][Full Text] [Related]
15. Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes.
Atroosh WM; Al-Mekhlafi HM; Snounou G; Al-Jasari A; Sady H; Nasr NA; Lau YL; Surin J
Malar J; 2016 May; 15(1):295. PubMed ID: 27234587
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of pfdhfr-pfdhps triple mutations associated with anti-malarial drugs resistance in Plasmodium falciparum isolates seven years after the adoption of sulfadoxine-pyrimethamine in combination with artesunate as first-line treatment in Iran.
Rouhani M; Zakeri S; Pirahmadi S; Raeisi A; Djadid ND
Infect Genet Evol; 2015 Apr; 31():183-9. PubMed ID: 25653131
[TBL] [Abstract][Full Text] [Related]
18. High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studies.
Adeel AA; Elnour FA; Elmardi KA; Abd-Elmajid MB; Elhelo MM; Ali MS; Adam MA; Atta H; Zamani G; Warsame M; Barrette A; Mohammady HE; Nada RA
Malar J; 2016 May; 15(1):285. PubMed ID: 27209063
[TBL] [Abstract][Full Text] [Related]
19. Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.
Malisa AL; Pearce RJ; Abdulla S; Mshinda H; Kachur PS; Bloland P; Roper C
Malar J; 2010 Jul; 9():190. PubMed ID: 20602754
[TBL] [Abstract][Full Text] [Related]
20. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
Plowe CV; Cortese JF; Djimde A; Nwanyanwu OC; Watkins WM; Winstanley PA; Estrada-Franco JG; Mollinedo RE; Avila JC; Cespedes JL; Carter D; Doumbo OK
J Infect Dis; 1997 Dec; 176(6):1590-6. PubMed ID: 9395372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
